← Eichor
Study identifier: NCT06242119 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Clinical Application of the J-PET Scanner Prototype

Condition: Prostate Cancer · Prostatic Hyperplasia · Prostatic Neoplasms  ·  Sponsor: Jagiellonian University

PhaseN/A
Planned participants25
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

Positron emission tomography (PET), an advanced diagnostic imaging technique, exploits the annihilation of positrons (e+) to delineate pathological alterations within diseased tissues. Integral to PET scanners are detector systems that transform gamma photons into fluorescent photons, thereby gleaning insights into the energy, time, and spatial distribution of gamma photons emanating from positron-emitting radiopharmaceuticals. Conventional PET scanners, bear a significant financial burden primarily due to their reliance on LSO (lutetium oxyorthosilicate) or LYSO (lutetium yttrium oxyorthosilicate) scintillation crystals. The exorbitant cost and limited availability of these crystal scintillators impede the widespread adoption of PET scanners. In a departure from conventional PET technology, the prototype J-PET scanner employed in this trial employs plastic scintillators, characterized by unique physical properties. This prototype is further equipped with bespoke software enabling three-photon imaging based on the annihilation of ortho-positronium (o-Ps) generated within diseased tissue. This study delves into the clinical applicability of PET scanners employing plastic scintillators, particularly investigating the feasibility of PET imaging using plastic scintillators where gamma quanta interact by mechanisms other than the photoelectric effect. Furthermore, this study endeavors to contemporaneously acquire and analyze data related to the lifetime of ortho-positronium (o-P) …

This description comes directly from the study's public registry record.

Talk to the study team

Pawel Moskal, PhD  ·  800-555-5555  ·  p.moskal@uj.edu.pl

Ewa Stepien, PhD  ·  800-555-5555  ·  e.stepien@uj.edu.pl

Always discuss trial participation with your own doctor first.

Locations (1)

Department of Endocrinology and Nuclear Medicine, University Hospital in KrakowKrakow, PolandRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06242119